Tri­bunal dis­miss­es Boehringer In­gel­heim's li­a­bil­i­ty claim against Sanofi in Zan­tac case

French phar­ma gi­ant Sanofi is not on the hook to in­dem­ni­fy Boehringer In­gel­heim for po­ten­tial li­a­bil­i­ties re­lat­ed to on­go­ing Zan­tac lit­i­ga­tion in the US, an In­ter­na­tion­al Cham­ber of Com­merce tri­bunal has ruled.

The tri­bunal dis­missed a claim brought by Boehringer In­gel­heim seek­ing in­dem­ni­fi­ca­tion for po­ten­tial loss­es, Sanofi an­nounced on Tues­day. The dis­pute traces back to 2017, when Sanofi ac­quired the rights to the over-the-counter heart­burn med Zan­tac from Boehringer In­gel­heim. About two years lat­er, the FDA is­sued a warn­ing that some ran­i­ti­dine med­i­cines, in­clud­ing over-the-counter Zan­tac, con­tain low lev­els of a prob­a­ble car­cino­gen called N-ni­troso­di­methy­lamine (ND­MA).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.